Biotech ETFs can help investors capitalize on health care innovation while avoiding the boom-or-bust nature of individual ...

Making its debut on 01/31/2006, smart beta exchange traded fund State Street SPDR S&P Biotech ETF (XBI) provides investors broad exposure to the Health Care ETFs category of the market. What Are Smart ...

Expense ratios, yield, and sector breadth set these healthcare ETFs apart—see how their risk profiles and portfolio strategies compare.

Amid the trying circumstances in the market right now, investors may be well served to target the best biotech ETFs to buy. Fundamentally, these exchange-traded funds benefit from permanent relevance.

Fri, April 3, 2026 at 2:17 PM UTC The biotech industry has been a robust roller-coaster over the last half decade. The State Street SPDR S&P Biotech ETF (NYSE: XBI), which tracks the biotech portion ...

Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. When it comes to biotech ETFs, they give sector participants exposure to many biotech companies via one ...

Biotech-based exchange-traded fund (ETF) iShares Biotechnology ETF IBB has rallied 26.1% over the past six months (as of Oct. 27, 2025), outperforming SPDR S&P 500 ETF Trust SPY (up 24.4%). Year to ...

State Street SPDR S&P Biotech ETF (XBI) gained +40.32% over the past year and equally weights roughly 145 stocks to provide exposure to smaller biotech companies. iShares Biotechnology ETF (IBB) ...

Biotech stocks are attracting investors as M&A activity, valuations and upcoming catalysts help drive sector momentum.

As anyone in the biotech investing space can tell you, picking winners in this corner of the healthcare market can be extremely difficult. Failed trials, FDA concerns, and pricing issues have hit a ...